Moffitt Cancer Center
Clarified Precision Medicine Acquires Molecular Diagnostics Firm Interpares Biomedicine
The acquisition brings Interpares' genetic sequencing test, OncoGuardian, into Clarified's portfolio of precision medicine products.
Apis Assay Technologies, Moffitt Cancer Center to Evaluate RNA Biomarkers for Cancer Progression
The group aims to determine the feasibility of TROLL-2 and TROLL-3 as diagnostic biomarkers for the prediction of treatment efficacy and prognosis in breast cancer.
Blood-Based Genetic Risk Score Shows Promise for Prostate Cancer Drug Response, Survival Prediction
Premium
The team envisions developing an assay to guide targeted treatment for metastatic castration-resistant prostate cancer patients.
Foreign Links at Moffitt to Be Investigated
The Tampa Bay Times reports that an investigation into foreign ties is being launched following the departure of the CEO, a vice president, and four researchers from the Moffitt Cancer Center.
Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.